These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 9145428)

  • 1. The long-acting vasoactive intestinal polypeptide agonist RO 25-1553 is highly selective of the VIP2 receptor subclass.
    Gourlet P; Vertongen P; Vandermeers A; Vandermeers-Piret MC; Rathe J; De Neef P; Waelbroeck M; Robberecht P
    Peptides; 1997; 18(3):403-8. PubMed ID: 9145428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interaction of lipophilic VIP derivatives with recombinant VIP1/PACAP and VIP2/PACAP receptors.
    Gourlet P; Rathé J; De Neef P; Cnudde J; Vandermeers-Piret MC; Waelbroeck M; Robberecht P
    Eur J Pharmacol; 1998 Jul; 354(1):105-11. PubMed ID: 9726637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological, molecular and functional characterization of vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide receptors in the rat pineal gland.
    Simonneaux V; Kienlen-Campard P; Loeffler JP; Basille M; Gonzalez BJ; Vaudry H; Robberecht P; Pévet P
    Neuroscience; 1998 Aug; 85(3):887-96. PubMed ID: 9639281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analogues of VIP, helodermin, and PACAP discriminate between rat and human VIP1 and VIP2 receptors.
    Gourlet P; Vandermeers A; Van Rampelbergh J; De Neef P; Cnudde J; Waelbroeck M; Robberecht P
    Ann N Y Acad Sci; 1998 Dec; 865():247-52. PubMed ID: 9928018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence for roles of vasoactive intestinal polypeptide (VIP) and pituitary adenylate cyclase activating polypeptide (PACAP) receptors in modulating the responses of rat dorsal horn neurons to sensory inputs.
    Dickinson T; Fleetwood-Walker SM; Mitchell R; Lutz EM
    Neuropeptides; 1997 Apr; 31(2):175-85. PubMed ID: 9179871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. C-terminally shortened pituitary adenylate cyclase-activating peptides (PACAP) discriminate PACAP I, PACAP II-VIP1 and PACAP II-VIP2 recombinant receptors.
    Gourlet P; Vandermeers A; Vandermeers-Piret MC; Rathé J; De Neef P; Robberecht P
    Regul Pept; 1996 Apr; 62(2-3):125-30. PubMed ID: 8795075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vasoactive intestinal peptide modification at position 22 allows discrimination between receptor subtypes.
    Gourlet P; Vandermeers-Piret MC; Rathé J; De Neef P; Cnudde J; Robberecht P; Waelbroeck M
    Eur J Pharmacol; 1998 May; 348(1):95-9. PubMed ID: 9650836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro properties of a high affinity selective antagonist of the VIP1 receptor.
    Gourlet P; De Neef P; Cnudde J; Waelbroeck M; Robberecht P
    Peptides; 1997; 18(10):1555-60. PubMed ID: 9437716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. VIP1 and VIP2 receptors but not PVR1 mediate the effect of VIP/PACAP on cytokine production in T lymphocytes.
    Jiang X; Wang HY; Yu J; Ganea D
    Ann N Y Acad Sci; 1998 Dec; 865():397-407. PubMed ID: 9928038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Properties of the pituitary adenylate cyclase-activating polypeptide I and II receptors, vasoactive intestinal peptide1, and chimeric amino-terminal pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal peptide1 receptors: evidence for multiple receptor states.
    Van Rampelbergh J; Gourlet P; De Neef P; Robberecht P; Waelbroeck M
    Mol Pharmacol; 1996 Dec; 50(6):1596-604. PubMed ID: 8967982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide receptor subtypes are differently expressed in rat transplanted pituitary tumours (SMtTW) and in the normal gland.
    Vertongen P; Delhase M; Rajas F; Trouillas J; Hooghe-Peters E; Svoboda M; Robberecht P
    J Mol Endocrinol; 1996 Jun; 16(3):239-48. PubMed ID: 8782082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pituitary adenylate cyclase activating polypeptide (PACAP I) and VIP (PACAP II VIP1) receptors stimulate inositol phosphate synthesis in transfected CHO cells through interaction with different G proteins.
    Van Rampelbergh J; Poloczek P; Françoys I; Delporte C; Winand J; Robberecht P; Waelbroeck M
    Biochim Biophys Acta; 1997 Jun; 1357(2):249-55. PubMed ID: 9223629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction of amino acid residues at positions 8-15 of secretin with the N-terminal domain of the secretin receptor.
    Gourlet P; Vilardaga JP; De Neef P; Vandermeers A; Waelbroeck M; Bollen A; Robberecht P
    Eur J Biochem; 1996 Jul; 239(2):349-55. PubMed ID: 8706739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fragments of pituitary adenylate cyclase activating polypeptide discriminate between type I and II recombinant receptors.
    Gourlet P; Vandermeers A; Vandermeers-Piret MC; Rathé J; De Neef P; Robberecht P
    Eur J Pharmacol; 1995 Dec; 287(1):7-11. PubMed ID: 8666028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of high affinity selective VIP1 receptor agonists.
    Gourlet P; Vandermeers A; Vertongen P; Rathe J; De Neef P; Cnudde J; Waelbroeck M; Robberecht P
    Peptides; 1997; 18(10):1539-45. PubMed ID: 9437714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vasoactive intestinal polypeptide receptor VPAC(1) subtype is predominant in rat prostate membranes.
    Juarranz MG; De Neef P; Robberecht P
    Prostate; 1999 Sep; 41(1):1-6. PubMed ID: 10440869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. VIP and pituitary adenylate cyclase activating polypeptide (PACAP) have an antiproliferative effect on the T98G human glioblastoma cell line through interaction with VIP2 receptor.
    Vertongen P; Camby I; Darro F; Kiss R; Robberecht P
    Neuropeptides; 1996 Oct; 30(5):491-6. PubMed ID: 8923513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A cloned frog vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide receptor exhibits pharmacological and tissue distribution characteristics of both VPAC1 and VPAC2 receptors in mammals.
    Alexandre D; Anouar Y; Jegou S; Fournier A; Vaudry H
    Endocrinology; 1999 Mar; 140(3):1285-93. PubMed ID: 10067855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maxadilan is a specific agonist and its deleted peptide (M65) is a specific antagonist for PACAP type 1 receptor.
    Uchida D; Tatsuno I; Tanaka T; Hirai A; Saito Y; Moro O; Tajima M
    Ann N Y Acad Sci; 1998 Dec; 865():253-8. PubMed ID: 9928019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Addition of the (28-38) peptide sequence of PACAP to the VIP sequence modifies peptide selectivity and efficacy.
    Gourlet P; Vandermeers A; Vandermeers-Piret MC; De Neef P; Robberecht P
    Int J Pept Protein Res; 1996 Oct; 48(4):391-6. PubMed ID: 8919060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.